Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H58N6O5 |
| Molecular Weight | 606.8401 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NC(C)(C)C
InChI
InChIKey=QMCOCIWNMHBIIA-LROMGURASA-N
InChI=1S/C32H58N6O5/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39)/t22-,23-,24-,25-,26-/m0/s1
| Molecular Formula | C32H58N6O5 |
| Molecular Weight | 606.8401 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tasidotin (also known as ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15. It was suggested, that tasidotin has a unique mechanism of action. The drug inhibits cell proliferation by suppressing spindle microtubule dynamics through a reduction of the shortening rate, reduction of the switching frequency from growth to shortening, and reduction of the time microtubules grow. Tasidotin was studied in clinical trials phase II in patients with locally advanced or metastatic non-small cell lung carcinoma, in patients with hormone-refractory prostate cancer, and in patients with inoperable locally advanced or metastatic melanoma. However, no new results were published last 5 years. It was suggested that tasidotin is no longer being used as single or even components of multiple agents today.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00082134
ILX651 (TASIDOTIN) administered Intravenously daily for five consecutive days every 21 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:08:43 GMT 2025
by
admin
on
Wed Apr 02 09:08:43 GMT 2025
|
| Record UNII |
05G07285DK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C25974
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9895066
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
DTXSID80940930
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
100000178313
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
C77067
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
C504233
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL2111109
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
8645
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
192658-64-3
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY | |||
|
05G07285DK
Created by
admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |